Gallium Maltolate is under clinical development by Titan Pharmaceuticals and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gallium Maltolate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gallium Maltolate overview
Gallium maltolate is under investigation for the treatment of relapsed and refractory glioblastoma, brain tumors and atypical teratoid rhabdoid tumor (ATRT). It was also under development for bone related disease such as osteoporosis, rheumatoid arthritis (RA), chronic bacterial infections and cancer such as hormone refractory prostate cancer, refractory multiple myeloma, refractory bladder cancer, and malignant lymphoma. Gallium maltolate a small molecule orally active compound for therapeutic use. Gallium maltolate is a coordination complex consisting of a trivalent gallium cation coordinated to three maltolate ligands. Gallium is antiproliferative to pathologically proliferating cells, particularly cancer cells and some bacteria, due primarily to its ability to mimic ferric iron (Fe3+). Ferric iron is essential for DNA synthesis, as it is present in the active site of the enzyme ribonucleotide reductase, which catalyzes the conversion of ribonucleotides to the deoxyribonucleotides required for DNA. Gallium maltolate is able to deliver gallium with high oral bioavailability. Gallium maltolate is administered by oral route.
Titan Pharmaceuticals overview
Titan Pharmaceuticals, Inc. (Titan) is a development stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology. Its product pipeline includes kappa opioid receptor agonists and nalmefene implants. It develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. The company also develops product candidates for the treatment of hormonal deficiencies including type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia, and others. It also partners with other companies for the delivery of other compounds using ProNeura technology. It also owns patents on its Proneura Technology platform across several countries. Titan is headquartered in South San Francisco, California, the US.
For a complete picture of Gallium Maltolate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
